Fatigue
Adjunctive testosterone ineffective for antidepressant-resistant MDD among women
Top 5 psychiatry stories of June
Watching Disney movies during chemotherapy may improve quality of life for women with gynecologic cancer
New onset fatigue develops in 26% of patients with IBD at 6 months
When there are (almost) no data
Afamelanotide may reduce symptoms, phototoxic reactions in erythropoietic protoporphyria
Q&A: What is ‘keto flu’?
Embracing the Placebo Effect: The Time has Arrived for Rheumatology
We are privileged to have a stellar group of discussants in this issue of Healio Rheumatology addressing the multiple facets of the placebo effect in the field of rheumatology. For a long time now, the ‘placebo effect’ has represented little more than a troublesome obstacle that clinical investigators — in the course of clinical trials with our growing armamentarium of therapeutics — must overcome to demonstrate that a drug or therapy is truly effective.
Few Americans aware of pulmonary fibrosis symptoms
Conversions from FACIT-F to PROMIS Fatigue feasible for RA clinical trials
Conversions of measurements from the Functional Assessment of Chronic Illness TherapyFatigue to the PatientReported Outcomes Measurement Information System Fatigue, or PROMIS Fatigue, is both feasible and applicable in clinical trials for RA, according to findings published in Arthritis Care & Research.